The management of colorectal cancer relies heavily on the combination of the pyrimidine
analog antimetabolite 5-fluorouracil with the platinum-based drug oxaliplatin or the …

3585 Background: Epidermal growth factor receptor (HER1/EGFR) overexpression occurs in
45–80% of CRC patients (pts). Erlotinib (Tarceva™) is a potent HER1/EGFR inhibitor …

Background Deregulation of protein translation control is a hallmark of cancers. Eukaryotic
initiation factor 4A2 (EIF4A2) is required for mRNA binding to ribosome and plays an …

Purpose: Results from clinical trials involving resistance to molecularly targeted therapies
have revealed the importance of rational single-agent and combination treatment strategies …

Objective As the new oral selective VEGFR tyrosine kinase inhibitor, axitinib (AG-013736)
exerts powerful antitumor activity in multiple solid tumors, while its' effect was unclear in …

Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with
KRAS G12C-mutant (MT) colorectal cancer. Thus, novel KRASG12C inhibitor combination …

The development of targeted therapies has revolutionized cancer treatment, offering
improved efficacy with reduced side effects compared with traditional chemotherapy. This …

Background Prognosis remains poor after progression on first-line chemotherapy for
colorectal adenocarcinoma, and inactivation of the EGFR pathway with monoclonal …

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous
5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study - PMC Back to Top …

Precision medicine is becoming considerably critical in colorectal cancer therapy.
Particularly for targeted therapies, the response to anti-EGFR therapy largely varies among …